Orthocell reports promising prostate cancer surgery results as Remplir targets US$2 billion market
Orthocell reported early results from a five-patient case series of Remplir nerve repair in prostate cancer surgery: 80% had positive urinary continence outcomes, and 75% of eligible patients showed a return of erectile function. The company said the findings support plans for a larger clinical trial and potential US market expansion.
Why it matters — The results could support Remplir’s development in prostate surgery and expand Orthocell’s estimated addressable market from US$1.6 billion to US$2 billion.